EME vs TRI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EMCOR Group (EME) presents a stable financial health profile with a Piotroski F-Score of 4/9 and an exceptionally low debt-to-equity ratio of 0.13. While the company demonstrates explosive earnings growth (53% YoY) and a stellar track record of EPS beats over 25 quarters, it trades at a massive premium to its Graham Number ($228.74) and is currently priced slightly above its growth-based intrinsic value ($831.31). The combination of bearish insider sentiment and a high Price-to-Book ratio (10.54) suggests that the stock is fully valued, leaving limited margin of safety for new investors.
TRI presents a stark contrast between operational health and valuation; while the Piotroski F-Score of 7/9 indicates strong internal financial health, the stock is trading at a massive premium to its Graham Number ($44.31) and Intrinsic Value ($23.03). A severe contraction in earnings growth (-42.6% YoY) and a high PEG ratio of 6.25 suggest the current price is not supported by current fundamentals. However, the company maintains a very conservative debt profile (Debt/Equity 0.20) and continues to receive bullish analyst support. The overall outlook is neutral as the operational strength provides a floor, but the valuation gap and earnings decline create significant headwinds.
Compare Another Pair
Related Comparisons
EME vs TRI: Head-to-Head Comparison
This page compares EMCOR Group, Inc. (EME) and Thomson Reuters Corporation (TRI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.